<DOC>
	<DOC>NCT01969747</DOC>
	<brief_summary>Placebo-controlled, double blind (triple-dummy technique), randomised parallel design comparison of three oral doses (2.5 mg, 10 mg, and 25 mg) of empagliflozin in patients with T1DM as adjunctive therapy to insulin over 28 days. Patients will undergo a 14-day open-label placebo run-in period before randomisation. Background insulin therapy will be kept stable during the first 7 days of the treatment period and will be freely adjusted thereafter.</brief_summary>
	<brief_title>Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criteria: Signed and dated written informed consent Male or female patient receiving insulin for treatment of T1DM for at least 12 months Cpeptide &lt; 1.5 ng/mL Age 18 to 65 years HbA1c of 7.5% to 10.5% Multiple daily injections (MDI) of any type of insulin Willing to follow an established and individualized carbohydrate counting method and an insulin administration algorithm Body Mass Index of 18.5 to 35.0 kg/m2 Estimated glomerular filtration rate 60 to 150 mL/min/1.73 mÂ² Able and willing to perform study assessments according to investigator's judgement Compliance with trial drug administration 80% to 120% during runin period Willing not to take any paracetamol containing drugs during the trial Exclusion criteria: Acute symptomatic urinary tract infection or genital infection, chronic or recurrent cystitis History of type 2 diabetes mellitus, maturity onset diabetes of the young (MODY), pancreatic surgery or chronic pancreatitis Pancreas, pancreatic islet cells or renal transplant recipient Type 1 diabetes mellitus treatment with any other antihyperglycaemic drug except insulin within last 3 months or history of clinically relevant hypersensitivity Occurrence of hypoglycaemia that required hospitalization or treatment by an emergency physician or paramedic within last 3 months Hypoglycaemia unawareness or frequent episodes of unexplained hypoglycaemia Occurrence of diabetic ketoacidosis that required hospitalization or treatment by an emergency physician or paramedic within last 12 months History of macrovascular disease including cardiovascular, cerebrovascular and peripheral artery disease Autonomic neuropathy with gastroparesis Brittle diabetes Liver disease Treatment with antiobesity drugs, surgery or aggressive diet regimen leading to unstable body weight Treatment with systemic corticosteroids Change in dose of thyroid hormones within last 6 weeks or planned change or initiation of such a therapy Medical history of cancer or treatment for cancer in the last five years Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells Alcohol or drug abuse that would interfere with trial participation or any ongoing clinical condition that would jeopardize patient's or site personnel's safety or study compliance Intake of an investigational drug in another trial within last 30 days Not able to understand and comply with study requirements Premenopausal women who are nursing or pregnant or of childbearing potential and are not practising an acceptable method of birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>